Work

Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases

Year: 2022

Type: article

Abstract: Scalp melanomas are associated with poor disease-related and survival outcomes compared with melanomas affecting other anatomical sites, partially due to high rates of in-transit metastases (ITM), defined as localized >2 cm from the primary tumor but not beyond draining lymph nodes.1,2 The standard treatment for ITMs is surgical excision3; however, surgery is often impractical for multiple or diffuse ITMs. Currently, the only Food and Drug Administration-approved therapy, specifically directed at ITMs is talimogene laherparepvec, an injectable modified oncolytic herpes simplex virus, which has shown modest response rates in phase III studies in patients with locally advanced melanoma.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2022.09.006